Literature DB >> 19720758

The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.

Melissa L Nguyen1, Simon Terzyan, Jimmy D Ballard, Judith A James, A Darise Farris.   

Abstract

Anthrax lethal and edema toxins (LeTx and EdTx, respectively) form by binding of lethal factor (LF) or edema factor (EF) to the pore-forming moiety protective antigen (PA). Immunity to LF and EF protects animals from anthrax spore challenge and neutralizes anthrax toxins. The goal of the present study is to identify linear B-cell epitopes of EF and to determine the relative contributions of cross-reactive antibodies of EF and LF to LeTx and EdTx neutralization. A/J mice were immunized with recombinant LF (rLF) or rEF. Pools of LF or EF immune sera were tested for reactivity to rLF or rEF by enzyme-linked immunosorbent assays, in vitro neutralization of LeTx and EdTx, and binding to solid-phase LF and EF decapeptides. Cross-reactive antibodies were isolated by column absorption of EF-binding antibodies from LF immune sera and by column absorption of LF-binding antibodies from EF immune sera. The resulting fractions were subjected to the same assays. Major cross-reactive epitopes were identified as EF amino acids (aa) 257 to 268 and LF aa 265 to 274. Whole LF and EF immune sera neutralized LeTx and EdTx, respectively. However, LF sera did not neutralize EdTx, nor did EF sera neutralize LeTx. Purified cross-reactive immunoglobulin G also failed to cross-neutralize. Cross-reactive B-cell epitopes in the PA-binding domains of whole rLF and rEF occur and have been identified; however, the major anthrax toxin-neutralizing humoral responses to these antigens are constituted by non-cross-reactive epitopes. This work increases understanding of the immunogenicity of EF and LF and offers perspective for the development of new strategies for vaccination against anthrax.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720758      PMCID: PMC2772542          DOI: 10.1128/IAI.00749-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  The development of new vaccines against Bacillus anthracis.

Authors:  L Baillie
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

3.  Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.

Authors:  Micah T McClain; Latisha D Heinlen; Gregory J Dennis; Jon Roebuck; John B Harley; Judith A James
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

4.  Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin.

Authors:  Stephen J Juris; Roman A Melnyk; Robert E Bolcome; Joanne Chan; R John Collier
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

5.  Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice.

Authors:  Aaron M Firoved; Georgina F Miller; Mahtab Moayeri; Rahul Kakkar; Yuequan Shen; Jason F Wiggins; Elizabeth M McNally; Wei-Jen Tang; Stephen H Leppla
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

6.  Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis.

Authors:  P Gupta; A Singh; V Chauhan; R Bhatnagar
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

7.  Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1.

Authors:  Isabelle I Salles; Daniel E Voth; Sabrina C Ward; Kathleen M Averette; Rodney K Tweten; Kenneth A Bradley; Jimmy D Ballard
Journal:  Cell Microbiol       Date:  2006-08       Impact factor: 3.715

8.  Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La (SS-B).

Authors:  A D Farris; L Brown; P Reynolds; J B Harley; J A James; R H Scofield; J McCluskey; T P Gordon
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

9.  Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin.

Authors:  Aaron M Firoved; Mahtab Moayeri; Jason F Wiggins; Yuequan Shen; Wei-Jen Tang; Stephen H Leppla
Journal:  Infect Immun       Date:  2007-03-05       Impact factor: 3.441

10.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

View more
  14 in total

Review 1.  Immunity to ricin: fundamental insights into toxin-antibody interactions.

Authors:  Joanne M O'Hara; Anastasiya Yermakova; Nicholas J Mantis
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  Mouse monoclonal antibodies to anthrax edema factor protect against infection.

Authors:  Clinton E Leysath; Kuang-Hua Chen; Mahtab Moayeri; Devorah Crown; Rasem Fattah; Zhaochun Chen; Suman R Das; Robert H Purcell; Stephen H Leppla
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

4.  Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.

Authors:  Eric K Dumas; Timothy Gross; Jason Larabee; Lance Pate; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Limone C Collins; Christina E Spooner; Hua Chen; Jimmy Ballard; Judith A James; A Darise Farris
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

5.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

6.  Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease.

Authors:  Faiz A Shakir; Tauseef Ali; Aletha C Bigham; Jimmy D Ballard; Philip B Miner; Jessica R Philpott
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

7.  Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.

Authors:  Mary Ann Pohl; Johanna Rivera; Antonio Nakouzi; Siu-Kei Chow; Arturo Casadevall
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

Review 8.  Anthrax lethal toxin and the induction of CD4 T cell immunity.

Authors:  Stephanie Ascough; Rebecca J Ingram; Daniel M Altmann
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

9.  Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.

Authors:  T Scott Devera; Sunil K Joshi; Lindsay M Aye; Gillian A Lang; Jimmy D Ballard; Mark L Lang
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.

Authors:  Lori Garman; Eric K Dumas; Sridevi Kurella; Jonathan J Hunt; Sherry R Crowe; Melissa L Nguyen; Philip M Cox; Judith A James; A Darise Farris
Journal:  Toxins (Basel)       Date:  2012-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.